Neparvis (Valsartan, Sacubitril)

Neparvis (sacubitril/valsartan) acts on the renin‑angiotensin‑aldosterone system and neprilysin pathway to manage cardiovascular conditions.

• Heart failure with reduced ejection fraction: improves survival and reduces hospitalizations by enhancing natriuresis and inhibiting cardiac remodeling.
• Hypertension: lowers blood pressure through vasodilation and natriuretic effects.

• Sacubitril/valsartan combines neprilysin inhibition by sacubitril with angiotensin II type‑1 receptor blockade by valsartan. Neprilysin inhibition increases circulating natriuretic peptides, leading to vasodilation, natriuresis, and inhibition of pathological cardiac remodeling, while angiotensin II blockade reduces vasoconstriction, aldosterone secretion, and sympathetic activation, together producing synergistic cardiovascular benefits.

Neparvis may cause a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Hypotension: symptomatic low blood pressure, often orthostatic.
• Hyperkalemia: elevated serum potassium levels.
• Renal impairment: rise in serum creatinine or reduced glomerular filtration.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or airway requiring immediate medical attention.
• Severe hypotension: profound blood pressure drop leading to syncope.
• Hepatic injury: abnormal liver enzymes or clinically apparent hepatitis.
• Acute renal failure: rapid decline in kidney function, especially in high‑risk patients.

Before initiating Neparvis, clinicians should evaluate patient-specific risk factors and monitor relevant parameters.

• Monitor blood pressure: ensure adequate control and avoid symptomatic hypotension.
• Assess renal function: check serum creatinine and eGFR prior to and during therapy.
• Check electrolytes: especially potassium levels to detect hyperkalemia.
• Avoid use in pregnancy: safety not established; discontinue if pregnancy occurs.
• Caution with concomitant ACE inhibitors or ARBs: stagger discontinuation to reduce angioedema risk.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Neparvis can interact with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• ACE inhibitors: concurrent use increases risk of angioedema.
• Other ARBs: duplicate renin‑angiotensin blockade may cause hypotension.
• Aliskiren (in diabetics): combined renin‑angiotensin inhibition raises renal adverse event risk.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effects; monitor volume status.
• Lithium: increased lithium concentrations; monitor serum levels and renal function.